Fulgent Reports Third Quarter 2024 Financial Results
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Business Wire
Total Revenue of $71.7 millionCore Revenue grows 9% year-over-year to $71.7 millionReiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024.Third Quarter 2024 Results:Total Revenue of $71.7 millionCore Revenue1 grew 9% year-over-year to $71.7 millionGAAP loss of $14.6 million, or ($0.48) per shareNon-GAAP income of $9.4 million, or $0.31 per shareAdjusted EBITDA income of $0.4 millionCash, cash equivalents, restricted cash, and investments in marketable securities of $815.4 million as of September 30, 2024Note: 1) Core Revenue is revenue calculated in accordance with GAAP minus revenue from COVID-19 testing products and services
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy [Yahoo! Finance]Yahoo! Finance
- Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology [Yahoo! Finance]Yahoo! Finance
- Oncology Specimen Provider Reference Medicine Announces Launch of Characterized Specimens, Enabling Increased Speed and Efficiency for Assay DevelopersPR Web
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
FLGT
Earnings
- 11/8/24 - Beat
FLGT
Sec Filings
- 11/8/24 - Form 10-Q
- 11/8/24 - Form 8-K
- 11/5/24 - Form SC
- FLGT's page on the SEC website